 |
12 Diseases |  |
17 Trials |
|
17 Trials |  |
2487 News |  |
| «12...13141516171819202122232425» |
- Emgality (galcanezumab) / Eli Lilly, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Effectiveness of Erenumab-aooe, Fremanezumab-vfrm and Galcanezumab-gnlm in Migraine Patients at Tertiary Headache Clinic with Emphasis on High-Frequency Migraine Patients () - Jan 21, 2020 - Abstract #AAN2020AAN_2943;
11/43 patients were hyper-responders and 5 patients went from 30 migraine days per month to zero. We conclude that this treatment should be considered in all patients even patients with refractory migraine who have high frequency migraine.
- Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
10-Year Cost-effectiveness Analyses of Fremanezumab Compared to Erenumab as Preventive Treatment in Episodic Migraine for Patients With Inadequate Response to Prior Preventive Treatments () - Jan 21, 2020 - Abstract #AAN2020AAN_2765;
We conclude that this treatment should be considered in all patients even patients with refractory migraine who have high frequency migraine. Based on current pricing and randomized controlled trial results, fremanezumab treatment is cost effective versus erenumab.
- Aimovig (erenumab) / Amgen, Novartis
Post marketing experiences with erenumab (Aimovig) for the treatment of chronic migraine in a real-life clinical setting () - Jan 21, 2020 - Abstract #AAN2020AAN_2414;
Based on current pricing and randomized controlled trial results, fremanezumab treatment is cost effective versus erenumab. Erenumab treatment resulted in reduced migraine frequency and disability in a population of refractory chronic migraine patients.
- Aimovig (erenumab) / Amgen, Novartis
The Aimovig “Wear-Off”: A Retrospective Case Series of Response to 14 day Dosing () - Jan 21, 2020 - Abstract #AAN2020AAN_2409;
Erenumab treatment resulted in reduced migraine frequency and disability in a population of refractory chronic migraine patients. For patients with Aimovig “Wear-Off”, switching therapy from Aimovig 140mg single monthly injections to 70mg injections every 14 days is an option that can potentially reduce monthly headache frequency and severity, while maintaining mild side effect profile.
- Aimovig (erenumab) / Amgen, Novartis
Ischemic Colitis Associated with Erenumab Use for Migraine () - Jan 21, 2020 - Abstract #AAN2020AAN_2264;
Other contributing factors included concurrent use of rizatriptan and amphetamines, which are both vasoconstrictive. Prescribers should be cautious of use of CGRP antagonists in patients with vasoconstrictive disease (Raynaud’s in this patient) and on multiple other vasoactive medications.
- Aimovig (erenumab) / Amgen, Novartis
First one–year real world evidence data with the monoclonal antibody Erenumab in Germany () - Jan 21, 2020 - Abstract #AAN2020AAN_2262;
Prescribers should be cautious of use of CGRP antagonists in patients with vasoconstrictive disease (Raynaud’s in this patient) and on multiple other vasoactive medications. The TELESCOPE study provides real world evidence data for erenumab in Germany regarding daily treatment routines , typical patient profiles and the effect on daily functioning and quality of life, both outcomes with great impact on migraine patients.
- Aimovig (erenumab) / Amgen, Novartis
First-Hand Impressions of the monoclonal Antibody in Migraine Prevention from Patients treated with Erenumab in Germany () - Jan 21, 2020 - Abstract #AAN2020AAN_2258;
The TELESCOPE study provides real world evidence data for erenumab in Germany regarding daily treatment routines , typical patient profiles and the effect on daily functioning and quality of life, both outcomes with great impact on migraine patients. PERISCOPE provides us the first real world evidence data of German patients treated with erenumab and reveals us a great insight into patients’ benefit and their experience with Erenumab.
- Aimovig (erenumab) / Amgen, Novartis
Long-term efficacy of erenumab in chronic migraine (CM) patients with or without acute medication overuse (AMO) () - Jan 21, 2020 - Abstract #AAN2020AAN_2097;
PERISCOPE provides us the first real world evidence data of German patients treated with erenumab and reveals us a great insight into patients’ benefit and their experience with Erenumab. CM patients with/without AMO treated with erenumab had sustained reductions in MMD with remission of overuse in ≥70% of cases.
- Vyepti (eptinezumab) / Lundbeck
Differences in Exposure Between Intravenously (IV) Administered Eptinezumab and Subcutaneously (SC) Administered CGRP Inhibitor Monoclonal Antibodies After Single Therapeutic Doses () - Jan 21, 2020 - Abstract #AAN2020AAN_1613;
The results indicate that, per mg of drug administered, eptinezumab is associated with 2.4-4.1-fold greater exposure than fremanezumab, galcanezumab, and erenumab (as assessed by Cmax) and 1.4-6.8-fold greater exposure (as assessed by AUC0-∞) when all agents were administered at single therapeutic doses. These data support a lower dose level and a prolonged administration schedule for eptinezumab when compared with these agents.
- Aimovig (erenumab) / Amgen, Novartis
First insights in real-world effectiveness of erenumab in chronic migraine patients with high burden of disease in Germany from the NTD headache and migraine registry () - Jan 21, 2020 - Abstract #AAN2020AAN_1088;
Erenumab is very well tolerated and achieves a responder rate >50% in patients with chronic high burden of disease and a history of up to 6 failed or contrainidicated prophylactic treatments. The NTD headache registry will enable more deeper insights into the care of migraine patients and treatment effectiveness as more data accumulate over time.
- Aimovig (erenumab) / Amgen, Novartis
Changes in Acute Migraine-specific Medications After Initiating Erenumab: Results from a Real-world Retrospective Cohort Study in the United States () - Jan 21, 2020 - Abstract #AAN2020AAN_1083;
In this US focused real-world study, a proportion of patients completing an adequate trial of erenumab discontinued and/or reduced consumption of their AMSMs. There is evidence that the benefits of erenumab seen in clinical trials, in terms of reductions in acute migraine-specific medications are being realized in real-world clinical practice.
- rimegepant (BHV-3000) / Portage
Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP Monoclonal Antibodies (mAb) Examining Health-related Quality of Life (HRQoL). () - Jan 21, 2020 - Abstract #AAN2020AAN_747;
Intermittent oral rimegepant was found to be superior to placebo and comparable to injectable galcanezumab and erenumab in reducing MIDAS, superior to placebo and erenumab in improving MSQOL, and generally comparable to galcanezumab in improving MSQOL. When adjustments were made to reflect baseline characteristics in published literature, current data suggest that rimegepant is an effective therapy in reducing disability and enhancing migraine specific HRQoL.
- rimegepant (BHV-3000) / Portage
Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP-targeted Monoclonal Antibodies Examining Monthly Migraine Days in the Treatment of Migraine () - Jan 21, 2020 - Abstract #AAN2020AAN_746;
Oral rimegepant was found to be superior to placebo and comparable to injectable galcanezumab and erenumab in reducing MMD. While a controlled trial would be the optimal methodology for assessing relative difference, the available data suggest that rimegepant may be effective in the prevention of migraine.
- Aimovig (erenumab) / Amgen, Novartis
The First, Italian, Multicenter, Real-life Study with Erenumab in the Prevention of High Frequency Episodic and Chronic Migraine () - Jan 21, 2020 - Abstract #AAN2020AAN_740;
In a real-life population of patients with HFEM and CM and multiple prior therapeutic failures erenumab 70 mg is more effective in terms of >50% response rate than reported in RCTs (HFEM: 63.8% vs 43%, CM: 66.3% vs 40%) and also largely outperforms the >50 response rate with the dose of 140 mg in patients with multiple therapeutic failures (LIBERTY trial: 30%). We confirm that erenumab is safe and well tolerated.
- rimegepant (BHV-3000) / Portage
Oral Rimegepant 75 mg Is Well-tolerated When Used Concomitantly with Injectable Anti-CGRP Monoclonal Antibodies: Results From a Multicenter, Long-term, Open-label Safety Study () - Jan 21, 2020 - Abstract #AAN2020AAN_643;
Rimegepant 75 mg, when used as an oral acute treatment in subjects receiving injectable anti-CGRP mAbs as preventive treatment, demonstrated favorable tolerability and no safety issues in this sample of adults with migraine. Larger sample sizes are needed to confirm these findings.
- Aimovig (erenumab) / Amgen, Novartis
Benefit of Migraine Prevention with Erenumab in Patients Receiving Background Standard-of-care Acute Treatment () - Jan 21, 2020 - Abstract #AAN2020AAN_641;
P2, P3
A post hoc analysis of AMSM users from two pivotal EM and CM trials demonstrated that preventive treatment with erenumab plus AMSM as needed significantly reduced MMDs, AMSM use, and disability (including HIT-6 and MIDAS) compared with AMSMs alone in placebo arms. These findings suggest the clinical benefit of effective prevention with erenumab over acute treatment alone in patients using AMSMs at baseline.
- Aimovig (erenumab) / Amgen, Novartis
Sustained Efficacy and Long-term Safety of Erenumab in Patients with Episodic Migraine: 4+ Year Results of a 5-year, Open-label Treatment Period () - Jan 21, 2020 - Abstract #AAN2020AAN_636;
These findings suggest the clinical benefit of effective prevention with erenumab over acute treatment alone in patients using AMSMs at baseline. In this interim analysis, long-term erenumab treatment (4+ years) demonstrated sustained reductions in migraine frequency and was well-tolerated and safe.
- Aimovig (erenumab) / Amgen, Novartis
Cardiovascular Safety of Erenumab in Patients with Migraine and Aura () - Jan 21, 2020 - Abstract #AAN2020AAN_586;
In this interim analysis, long-term erenumab treatment (4+ years) demonstrated sustained reductions in migraine frequency and was well-tolerated and safe. The vascular safety profile of long-term erenumab treatment was similar in patients both with and without history of aura and was comparable to that of placebo over 12 weeks, with no increased emergence of events over time.
- Emgality (galcanezumab) / Eli Lilly, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Adverse Event Profiles of Therapies that Target the Calcitonin Gene-Related Peptide (CGRP) Pathway, During the First Six Months After Launch: A Real-world Data Analysis Using the FDA Adverse Events Reporting System (FAERS) () - Jan 21, 2020 - Abstract #AAN2020AAN_584;
Constipation ranked second for erenumab but did not make the top ten AEs for fremanezumab or galcanezumab. Cardiovascular events were not ranked in the top ten for any of the products.
- Aimovig (erenumab) / Amgen, Novartis
Migraine Polygenic Risk Score Is Associated with Severity of Migraine – Analysis of Genotypic Data from Four Placebo-controlled Trials of Erenumab () - Jan 21, 2020 - Abstract #AAN2020AAN_454;
Based on mPRS, migraine/nonmigraine headache frequency does not appear to have a strong genetic underpinning. mPRS-dependent phenotypic differences include earlier age of onset and greater likelihood of treatment with acute/preventive medications, suggesting that migraine patients with greater genetic predisposition may have greater disease severity.
- ||| Aimovig (erenumab) / Amgen, Novartis
Hey, @Novartis @Amgen the way you package Aimovig ® is a huge waste, you could do just as well and probably save money if you reduced the packaging by half (Twitter) - Jan 20, 2020
- || Aimovig (erenumab) / Amgen, Novartis
Retrospective data, Review, Journal: Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomized clinical trials. (Pubmed Central) - Jan 16, 2020
mPRS-dependent phenotypic differences include earlier age of onset and greater likelihood of treatment with acute/preventive medications, suggesting that migraine patients with greater genetic predisposition may have greater disease severity. Among patients with migraine, both 70 and 140 mg of erenumab were associated with reduced Migraine-specific medication days, Migraine-specific medication days from baseline, and an increased rate of a 50% reduction, in the absence of an increased risk of any serious adverse effect.
- | Aimovig (erenumab) / Amgen, Novartis
Journal: Migraine day frequency in migraine prevention: longitudinal modelling approaches. (Pubmed Central) - Jan 16, 2020
P2, P3
Modelling MMD using negative binomial and beta-binomial distributions can be advantageous because these models can capture intra- and inter-patient variability so that trial observations can be modelled parametrically for the purposes of economic evaluation of migraine prevention. Such models have implications for use in a wide range of disease areas when assessing repeated measured utility values.
- | Journal: Migraine treatment: the doors for the future are open, but with caution and prudence. (Pubmed Central) - Jan 13, 2020
In addition, there were deaths during the studies, which may have happened without a clear relationship. New treatments are welcome, but caution is warranted.
- || Aimovig (erenumab) / Amgen, Novartis
Tell @NICEComms to listen to @UK_headache and @theABN_Info and approve Aimovig for the NHS. Appeal results due in 2-4 weeks. (Twitter) - Jan 2, 2020
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. (Pubmed Central) - Jan 1, 2020
P2
New treatments are welcome, but caution is warranted. Erenumab reduced migraine frequency and acute migraine-specific medication treatment days in patients with chronic migraine and medication overuse, improving disability and quality of life.
- | Aimovig (erenumab) / Amgen, Novartis
Thats dreadful! Do you think you may just be allergic to Aimovig? (Twitter) - Jan 1, 2020
- || Botox (onabotulinumtoxin A) / GSK, Allergan, Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal, HEOR: Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece. (Pubmed Central) - Dec 25, 2019
The prophylactic treatment of CM with erenumab in Greece might be cost effective compared to the existing alternative of onabotulinumtoxinA from both the payer and the societal perspective, but only at a highly discounted price. Nevertheless, erenumab could be considered a therapeutic option for patients who fail treatment with onabotulinumtoxinA.
- | Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. (Pubmed Central) - Dec 23, 2019
P2
Nevertheless, erenumab could be considered a therapeutic option for patients who fail treatment with onabotulinumtoxinA. Erenumab-treated patients with CM experienced clinically relevant improvements across a broad range of patient-reported outcomes.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report. (Pubmed Central) - Dec 23, 2019
We describe a 41-year-old woman with migraine without aura who developed a right thalamic infarction following a first dose of erenumab, a CGRP-receptor blocker...Extensive evaluation revealed no other specific cause of stroke or vascular risk factors aside from long-term use of oral contraceptive pills. CGRP inhibitors might be associated with ischemic stroke due to blockade of normal cerebral vasodilatory regulatory function.
- | Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Erenumab: from scientific evidence to clinical practice-the first Italian real-life data. (Pubmed Central) - Dec 20, 2019
CGRP inhibitors might be associated with ischemic stroke due to blockade of normal cerebral vasodilatory regulatory function. No abstract available
- |||| Aimovig (erenumab) / Amgen, Novartis
Adverse events: Female victims of Aimovig. So many of us are suffering from this drug. You did no long term studies and only listed constipation as a side effect. My lawyers and I will not rest until this drug is off the market. It nearly killed me. (Twitter) - Dec 19, 2019
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: EMPOwER: Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients (clinicaltrials.gov) - Dec 18, 2019
P3, N=900, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
No abstract available Recruiting --> Active, not recruiting
- | Botox (onabotulinumtoxin A) / GSK, Allergan, Aimovig (erenumab) / Amgen, Novartis
Not at all helping my apprehension about trying botox treatment. 😱 I can't afford Aimovig. 🙁 (Twitter) - Dec 7, 2019
- | Botox (onabotulinumtoxin A) / GSK, Allergan, Aimovig (erenumab) / Amgen, Novartis
You self inject #Aimovig at home therefore freeing up valuable time for #neurologists & #nurses. #Botox has to be administered in a clinic by a specialist. (Twitter) - Dec 7, 2019
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine (clinicaltrials.gov) - Dec 5, 2019
P4, N=340, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Aimovig (erenumab) / Amgen, Novartis
Toda la razón. Estaba pensando en el Erenumab. (Twitter) - Dec 5, 2019
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients (clinicaltrials.gov) - Dec 5, 2019
P4, N=600, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Trial completion date: Jan 2021 --> Jul 2021 | Trial primary completion date: Dec 2020 --> Jun 2021
- || Aimovig (erenumab) / Amgen, Novartis
We few, we happy few... off to storm the breach at @NICEComms to try to get #erenumab approved for use on the NHS in England and Wales. @petergoadsby @IIHDrBirmingham and I will argue that the original assessment was flawed and should be revised. Updates will follow... (Twitter) - Dec 4, 2019
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: OLTP: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention (clinicaltrials.gov) - Dec 3, 2019
P2, N=484, Completed, Sponsor: Amgen
Trial completion date: Jan 2021 --> Jul 2021 | Trial primary completion date: Dec 2020 --> Jun 2021 Active, not recruiting --> Completed
- || Ubrelvy (ubrogepant) / AbbVie
New P1 trial: Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine (clinicaltrials.gov) - Nov 27, 2019
P1b, N=40, Recruiting, Sponsor: Allergan
- || Aimovig (erenumab) / Amgen, Novartis
Having a little problem w the #Aimovig cartridges .@Amgen, or, more accurately, a couple of problems 1/ (Twitter) - Nov 25, 2019
- || Aimovig (erenumab) / Amgen, Novartis
Clinical: Hi, you are so right! we are a group of patients calling for Aimovig on the NHS. Trying to raise awareness and get the word out #benicethinktwice (Twitter) - Nov 22, 2019
- | Aimovig (erenumab) / Amgen, Novartis
Review, Journal: CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review. (Pubmed Central) - Nov 22, 2019
CGRP antagonists appear to significantly improve treatment outcomes in patients who suffer from episodic and chronic migraines. Erenumab is the first CGRP antagonist to be FDA approved for public use; however, further development of biologics in this class is underway.
- |||| Emgality (galcanezumab) / Eli Lilly, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Clinical: @JenniferRobblee @eloder @mrobbinsmd @headachedoc Comparison of 3 CGRP mabs based on my year's worth of personal experience. Winner $TEVA's Ajovy - best efficacy & best AE profile. $AMGN's Aimovig constipation (CGRP receptors in gut). $LLY's Emgality bad injection site reaction (Twitter) - Nov 21, 2019
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Consideration of Costs and Open-Label Studies of Erenumab. (Pubmed Central) - Nov 21, 2019
Erenumab is the first CGRP antagonist to be FDA approved for public use; however, further development of biologics in this class is underway. No abstract available
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Consideration of Costs and Open-Label Studies of Erenumab-Reply. (Pubmed Central) - Nov 21, 2019
No abstract available No abstract available
- || Botox (onabotulinumtoxin A) / GSK, Allergan, Aimovig (erenumab) / Amgen, Novartis
@NICEComms @UK_headache @MigraineTrust my experience so far 5 months in with combining #botox and #Aimovig (Twitter) - Nov 20, 2019
- || Aimovig (erenumab) / Amgen, Novartis
En el Congreso de la #SEN en #Sevilla se habla del primer medicamento #Aimovig (erenumab) de @novartis incluido en el Sistema Nacional de Salud. Se trata de un tratamiento preventivo de la #migraña vía @Elmedicoint @nekanelauzirika (Twitter) - Nov 20, 2019
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia (clinicaltrials.gov) - Nov 20, 2019
P2, N=80, Recruiting, Sponsor: Danish Headache Center
No abstract available Not yet recruiting --> Recruiting